Ross A. Soo
National University Cancer Institute, Singapore(SG)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study(2018)775 cited
- → De-novo and acquired resistance to immune checkpoint targeting(2017)723 cited
- → Isolation and retrieval of circulating tumor cells using centrifugal forces(2013)719 cited
- → Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis(2012)669 cited
- → Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial(2020)592 cited
- → Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study(2018)570 cited
- → Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer(2013)555 cited
- → A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer(2012)552 cited
- → ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer(2019)375 cited
- → Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial(2019)350 cited